{
    "clinical_study": {
        "@rank": "153086", 
        "acronym": "LMWHCR", 
        "arm_group": [
            {
                "arm_group_label": "ARM A", 
                "arm_group_type": "Experimental", 
                "description": "Low-molecular-weight heparin (nadroparin 5000IU)was injected by  subcutaneous injections for 7 days after surgery daily."
            }, 
            {
                "arm_group_label": "ARM  B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (NS) was injected by subcutaneous injections for 7 days after surgery daily."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of low-molecular-weight\n      heparin in the prevention of venous thromboembolism and improvement of disease-free survival\n      in patients after surgery for colorectal cancer."
        }, 
        "brief_title": "The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Colorectal Cancer", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Colorectal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "A consecutive patients after surgery for colorectal cancer from ZhongShan hospital, Fudan\n      university were enrolled and randomly assigned to taking low-molecular-weight or placebo.\n      Post-operative formation of venous thromboembolism, major and minor bleeding, disease-free\n      survival were compared."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 18 and \u2264 75 years;\n\n          2. Primary tumour has undergone radical resection and histologically confirmed\n             colorectal adenocarcinoma;\n\n          3. without other organ metastasis or peritoneum metastasis\n\n          4. without contradiction of cardiac and pulmonary diseases\n\n          5. without prior venous thromboembolism and history of taking anticoagulant drugs\n\n          6. without contraindications to heparin therapy\n\n          7. Performance status (ECOG) 0~1\n\n          8. Written informed consent for participation in the trial.\n\n          9. Adequate hematological function: Neutrophils\u22651.5 x109/l and platelet count\u2265100\n             x109/l; Hb \u22659g/dl (within 1 week prior to randomization)\n\n         10. Adequate hepatic and renal function: Serum bilirubin\u22641.5 x upper limit of normal\n             (ULN), alkaline phosphatase \u22645x ULN, and serum transaminase (either AST or ALT) \u2264 5 x\n             ULN(within 1 week prior to randomization);\n\n        Exclusion Criteria:\n\n          1. unresectable primary colorectal tumor or liver metastasis\n\n          2. with other organ metastasis or peritoneum metastasis\n\n          3. with contradiction of cardiac or pulmonary disease\n\n          4. with prior venous thromboembolism or history of taking anticoagulant drugs\n\n          5. with contraindications to heparin therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01972490", 
            "org_study_id": "LMWHCRM"
        }, 
        "intervention": [
            {
                "arm_group_label": "ARM A", 
                "description": "nadroparin 5000IU/day was injected by subcutaneous injections for 7 days after surgery.", 
                "intervention_name": "Nadroparin", 
                "intervention_type": "Drug", 
                "other_name": "one kind of low molecular weight heparin"
            }, 
            {
                "arm_group_label": "ARM  B", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin", 
                "Heparin, Low-Molecular-Weight", 
                "Dalteparin", 
                "Nadroparin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "colorectal neoplasms", 
            "low-molecular-weight heparin"
        ], 
        "lastchanged_date": "October 29, 2013", 
        "location": {
            "contact": {
                "email": "xujmin@aliyun.com", 
                "last_name": "jianmin xu, MD", 
                "phone": "008613501984869"
            }, 
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200000"
                }, 
                "name": "Zhongshan Hospital, Fudan University"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Study of The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Colorectal Cancer", 
        "overall_contact": {
            "email": "xujmin@aliyun.com", 
            "last_name": "jianmin Xu, MD", 
            "phone": "008613501984869"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Venous thromboembolism: symptomatic deep vein thrombosis, pulmonary embolism. Major bleeding: an overt bleeding which was fatal, occurred in a critical organ.\nMinor bleeding: any overt bleeding that required a medical intervention and did not meet any of the criteria for major bleeding.", 
            "measure": "the rate of venous thromboembolism, the rate of major and minor bleeding", 
            "safety_issue": "Yes", 
            "time_frame": "1 month  after the operation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01972490"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Xu jianmin", 
            "investigator_title": "Jianmin Xu, PhD Fudan University", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "PFS will be defined as the period from the first day of CRC resection to local or distant(i.e. metastasis) disease recurrence or death.", 
                "measure": "3 years disease-free survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years after operation of colorectal cancer"
            }, 
            {
                "description": "OS will be calculated from randomization to death from any cause or the date of the last follow-up, at which point the data will be censored.", 
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "3 years"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Xu jianmin", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2009", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}